ArticleMedicine2017

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.

Pei-Chien Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.